363 related articles for article (PubMed ID: 33250497)
1. Development of an in vivo-mimic silkworm infection model with Mycobacterium avium complex.
Yagi A; Yamazaki H; Terahara T; Yang T; Hamamoto H; Imada C; Tomoda H; Uchida R
Drug Discov Ther; 2021 Jan; 14(6):287-295. PubMed ID: 33250497
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Nosiheptide, Griseoviridin, and Etamycin as Potent Anti-Mycobacterial Agents against Mycobacterium avium Complex.
Hosoda K; Koyama N; Kanamoto A; Tomoda H
Molecules; 2019 Apr; 24(8):. PubMed ID: 30995807
[No Abstract] [Full Text] [Related]
3. Evaluation of Anti-Mycobacterial Compounds in a Silkworm Infection Model with
Hosoda K; Koyama N; Hamamoto H; Yagi A; Uchida R; Kanamoto A; Tomoda H
Molecules; 2020 Oct; 25(21):. PubMed ID: 33121091
[TBL] [Abstract][Full Text] [Related]
4. Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis.
Yagi A; Uchida R; Hamamoto H; Sekimizu K; Kimura KI; Tomoda H
J Antibiot (Tokyo); 2017 May; 70(5):685-690. PubMed ID: 28446822
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Huang CC; Wu MF; Chen HC; Huang WC
J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
[TBL] [Abstract][Full Text] [Related]
6. New liposidomycin congeners produced by Streptomyces sp. TMPU-20A065, anti-Mycobacterium avium complex agents with therapeutic efficacy in a silkworm infection model.
Yagi A; Fujiwara M; Sato M; Abe Y; Uchida R
J Antibiot (Tokyo); 2024 Jul; 77(7):412-421. PubMed ID: 38720140
[TBL] [Abstract][Full Text] [Related]
7. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
8. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
9. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
[TBL] [Abstract][Full Text] [Related]
10. Comparing the Genotype and Drug Susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China.
Zheng HW; Pang Y; He GX; Song YY; Zhao YL
Biomed Environ Sci; 2017 Jul; 30(7):517-525. PubMed ID: 28756811
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model.
Petersen EA; Grayson JB; Hersh EM; Dorr RT; Chiang SM; Oka M; Proffitt RT
J Antimicrob Chemother; 1996 Nov; 38(5):819-28. PubMed ID: 8961051
[TBL] [Abstract][Full Text] [Related]
12. [Antimicrobial susceptibility and genotyping of
Wang SQ; Jiang GL; Wei GM; Huo FM; Dong LL; Zhao LP; Huang HR; Wang GR
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Jul; 41(7):539-543. PubMed ID: 29996350
[No Abstract] [Full Text] [Related]
13. Mavintramycin A is a promising antibiotic for treating
Hosoda K; Koyama N; Shigeno S; Nishimura T; Hasegawa N; Kanamoto A; Ohshiro T; Tomoda H
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0091723. PubMed ID: 38334410
[No Abstract] [Full Text] [Related]
14. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.
Mehta RT
Antimicrob Agents Chemother; 1996 Aug; 40(8):1893-902. PubMed ID: 8843300
[TBL] [Abstract][Full Text] [Related]
15. [Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
Ogawa K; Sano C
Kekkaku; 2013 Mar; 88(3):355-71. PubMed ID: 23672176
[TBL] [Abstract][Full Text] [Related]
16. The beige mouse model for Mycobacterium avium complex (MAC) disease: optimal conditions for the host and parasite.
Gangadharam PR; Perumal VK; Farhi DC; LaBrecque J
Tubercle; 1989 Dec; 70(4):257-71. PubMed ID: 2626803
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan.
Yamaba Y; Ito Y; Suzuki K; Kikuchi T; Ogawa K; Fujiuchi S; Hasegawa N; Kurashima A; Higuchi T; Uchiya KI; Watanabe A; Niimi A
J Infect Chemother; 2019 Dec; 25(12):995-1000. PubMed ID: 31239192
[TBL] [Abstract][Full Text] [Related]
18. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Jul; 66(7):489-92. PubMed ID: 1890791
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China.
Zhao X; Wang Y; Pang Y
Infect Genet Evol; 2014 Oct; 27():332-8. PubMed ID: 25131955
[TBL] [Abstract][Full Text] [Related]
20. Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.
Andréjak C; Almeida DV; Tyagi S; Converse PJ; Ammerman NC; Grosset JH
Antimicrob Agents Chemother; 2015 Apr; 59(4):2129-35. PubMed ID: 25624335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
